The most common alterations in our DCIS biobank include ERBB2 amplifications (34.8%) and mutations in TP53 (24.7%), PIK3CA (24.7%), GATA3 (18.0%), and AKT1 (12.4%) (Figure 2A). Here, ERBB2 is linked to ductal breast carcinoma in situ.